STAT3 and non-small cell lung carcinoma: In gefitinib-resistant NSCLC cells, inhibition of STAT3 reduces PDL1 expression [299], and enhances the efficacy of anti-PD1/PDL1 immunotherapies in NSCLC tumor-bearing mice [81].